Stem Cell Transplant Complications Clinical Trial
Official title:
Oral Complications After Haematopoietic Stem Cell Transplantation: a Retrospective Study
Haematopoietic stem cell transplantation (HSCT) is a potentially lifesaving treatment option for various diseases. It involves infusion of stem cells after a conditioning regimen of chemotherapy with or without total body irradiation. There is a concern that HSCT and accompanying treatments may increase the risk for oral complications. Nevertheless, longitudinal studies measuring oral health before and after HSCT are scarce. Hence, we formulated the following research question: In adult HSCT recipients, do oral health parameters change from baseline (pre-HSCT) to 3 - 24 months post-HSCT, and is the type of conditioning regimen associated with this change in oral health parameters? To answer this research question, we will use data from the electronic health records of the Radboudumc (Epic and Dentium). We will include at least seventy-five adult patients who are examined both before and after HSCT at the department of Dentistry (Radboudumc) as part of an oral care program. The following oral health parameters were assessed: status praesens, pocket probing depth, bleeding on probing, periodontal epithelial surface area, periodontal inflamed surface area, xerostomia, unstimulated and stimulated salivary flow rate and pH, cariesactivity, oral chronic Graft-versus-Host Disease and dental treatments. Patients were subjected to different regimens in preparation for HSCT, namely myeloablative, reduced intensity or non-myeloablative conditioning. To estimate the association between conditioning regimen and the change in oral health parameters, we will use mixed effects models with random effects, adjusted for potential confounders. Results will be reported as regression coefficients with corresponding 95% confidence intervals.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
| Recruiting |
NCT06080490 -
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
|
||
| Completed |
NCT03042676 -
Electronic Database for the Follow up of the ATG_FamilyStudy
|
||
| Recruiting |
NCT03871296 -
DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
|
||
| Not yet recruiting |
NCT06022445 -
Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
|
||
| Recruiting |
NCT04502628 -
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT
|
N/A | |
| Recruiting |
NCT03793517 -
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
|
Phase 2/Phase 3 | |
| Completed |
NCT03454568 -
The Patients' Experience After Stem Cell Transplant
|
||
| Recruiting |
NCT05466201 -
The Use of Eltrombopag Post HSCT in BMFS
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04080622 -
Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.
|
Phase 3 | |
| Recruiting |
NCT05523336 -
Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
|
||
| Completed |
NCT03355235 -
Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
|
||
| Completed |
NCT04888286 -
DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
|
||
| Not yet recruiting |
NCT05421416 -
Loratadine for the Prevention of G-CSF-related Bone Pain
|
Phase 2 | |
| Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
| Active, not recruiting |
NCT03967665 -
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution
|
Phase 3 | |
| Withdrawn |
NCT05104268 -
Study of a New Medical Device for Oral Mucositis
|
Early Phase 1 | |
| Recruiting |
NCT04623424 -
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
|
||
| Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
| Completed |
NCT03489551 -
Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
|
Phase 4 |